Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition globally, but is often hidden or misdiagnosed in routine clinical care, according to the American Heart Association's (AHA) first scientific statement on NAFLD published in the June edition of Arteriosclerosis, Thrombosis, and Vascular Biology.
In the statement, authors reviewed the underlying risk factors and pathophysiology of NAFLD, diagnostic and screening strategies, potential interventions, and current treatments. Below, find 7 questions based on the authors' key take-home messages for health care professionals.
1. NAFLD is estimated to affect approximately 15% of the global adult population.